BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for IBD
BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a collaboration with Boehringer Ingelheim to utilize the […]